Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Durvalumab in Indian Patients with Locally Advanced NSCLC
NCT04416633Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04416633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416633.